The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients

Figure 1

A case of breast carcinoma in group 1 (tamoxifen sensitive) with serum AGR2 level 3 ng/ml showed negative SOX2 expression (a) and negative AGR2 expression (b). Another case of group 1 with serum AGR2 level 7 ng/ml showed low SOX2 nuclear positivity score 3 (c) and low AGR2 cytoplasmic positivity score 2 (d) in malignant cells (X100).

(a)

(b)

(c)

(d)